Accuray Inc (Accuray) is a radiation oncology company that manufactures, develops, and sells treatment solutions for advanced treatments such as stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), image-guided radiation therapy (IGRT), and adaptive radiation therapy. The company operates through one reportable segment. It offers CyberKnife Systems that delivers stereotactic body radiation therapy, and stereotactic radiosurgery and is used for the treatment of various types of cancer and tumor.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Accuray’s R&D efforts focus on driving product differentiation, expanding clinical applications, and improving the usability, interoperability, reliability, and performance of its products. Major technology includes CyberKnife and TomoTherapy Systems. In FY2023, the company spent US$57.1 million on R&D activities. As of June 2023, the company had around 439 US and foreign patents; and over 159 US and foreign patent applications.